Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06784193 is registered in ClinicalTrials.gov with Olema Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06784193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06784193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
Olema Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 16, 2024
Completion date
August 30, 2027
Enrollment
180 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic castration-resistant prostate cancer (mcrpc), advanced or metastatic er+ her2- breast cancer (mbc), advanced or metastatic non-small cell lung cancer (nsclc), fulvestrant, metastatic breast cancer, palazestrant